Curantil 25 - instructions for use, dose, side effects, contraindications

Excipients: corn starch 11.750 mg, lactose monohydrate 11.00 mg, magnesium stearate 1.250 mg, talc 0.50 mg, gelatin 1.00 mg, silicon colloidal dioxide 0.50 mg.

Sheath: sucrose - 24,314 mg, calcium carbonate - 3,796 mg, magnesium hydroxycarbonate - 1,322 mg, talc - 1,322 mg, macrogol 6000 - 1,536 mg, dextrose liquid (dry weight) - 1,456 mg, titanium dioxide - 1,024 mg, povidone (value of K = 25 ) - 0.213 mg, carnauba wax 0.011 mg, quinoline yellow color, E 104 0.006 mg.

Description:

The tablets are covered with a shell, round in shape from yellow to greenish-yellow with a smooth smooth surface.

Pharmacotherapeutic group:Vasodilator

ATX: & nbsp

B.01.A.C.07 Dipyridamole

Pharmacodynamics:

Dipyridamole is an antagonist of the endogenous adenosine diphosphate (ADP) aggregate, inhibits phosphodiesterase, while the release of platelets is reduced aggregation activators - thromboxane, ADP, serotonin, etc., increases the synthesis of prostacyclin PgI2 endothelium of the vascular tissue, which hinders the aggregation of platelets. Reduces adhezivnost platelets, prevents the formation of blood clots in the vessels, stabilizes the blood flow in the source of ischemia. Dose-dependent extends the abnormally shortened lifetime of thrombocytes.

Has vasodilator effect, improves microcirculation and angiogenesis. Normalizes venous outflow, reduces the incidence of deep vein thrombosis in the postoperative period. Improves microcirculation in the retina of the eye, kidney glomeruli. Reduces the tone of the cerebral vessels, it is effective for dynamic disorders of cerebral circulation.

In obstetrical practice, they are used to correct placental blood flow, prevent dystrophic changes in the placenta, eliminate hypoxia of the fetal tissues and promote the accumulation of glycogen in them.

As a pyrimidine derivative, dipyridamole is an interferon inducer and has a modulating effect on the functional activity of the interferon system, increases the decreased production of interferon alpha (a) and gamma (y) by blood leukocytes in vitro. Dipiridamol increases non-specific antiviral resistance to viral infections.

Pharmacokinetics:

Ingestion dipyridamole quickly absorbed in the stomach (most) and partially in the small intestine. The maximum concentration (C_max) dipyridamole in the blood plasma is reached within 1 hour after ingestion. Dipyridamole almost completely binds to blood proteins.

It accumulates in large quantities in the heart and in red blood cells. The half-life (T_1/2) is 20-30 minutes. Dipyridamole is metabolized in the liver with the formation of monoglyukuronide, which is excreted with bile.

Indications:

- Treatment and prevention of cerebral circulatory disorders by ischemic type, dyscirculatory encephalopathy;

- prophylaxis of arterial and venous thromboses and their complications, prophylaxis of thromboembolism after the operation of prosthetic heart valves;

- prevention of placental insufficiency in a complicated pregnancy;

- in the complex therapy for any violations of microcirculation;

- as an inducer of interferon and immunomodulator for the prevention of influenza, acute respiratory viral infections (ARVI).

Contraindications:

- Acute myocardial infarction, unstable angina, common stenosing coronary artery atherosclerosis;

- subaortic stenosis;

- Decompensated heart failure;

- arterial hypotension, collapse;

- severe arterial hypertension;

- severe arrhythmias;

- hemorrhagic diathesis;

- diseases with a tendency to bleeding (peptic ulcer of the stomach and duodenum, etc.);

- chronic obstructive pulmonary disease (COPD);

- hepatic and / or renal insufficiency;

- hypersensitivity to the components of the drug;

- sugarase / isomaltase deficiency, fructose intolerance, lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

- children under 12 years of age (efficacy and safety of the drug are not established).

Pregnancy and lactation:

The use of the drug during pregnancy and lactation is possible only if the intended benefit to the mother exceeds the possible risk to the fetus and the baby.

Dosing and Administration:

If the doctor is not assigned otherwise, the following dosing regimens are recommended: To reduce platelet aggregation, it is recommended to take Curantil® 25 at a dose of 75-225 mg / day in several doses. In severe cases, the dose may be increased to 600 mg / day.

To prevent placental insufficiency, it is recommended to take Curantil® 25 at a dose of 25 mg (1 tablet) 3 times a day. The maximum daily dose of 225 mg.

The length of the course of therapy and the possibility of a repeat course are determined by the doctor.

For the prevention of influenza and other acute respiratory viral infections, especially during epidemics, take Kurantil® 25 as follows: 50 mg per day (2 tablets of 25 mg) once every 7 days for 4-5 weeks.

To prevent relapses in patients with respiratory viral infections often infected with patients, Curantil® 25 is recommended to be taken as follows: 100 mg per day (2 times 2 tablets at intervals of 2 hours) once a week for 8-10 weeks. Curantil® 25 is recommended to be taken on an empty stomach without snapping, squeezed with a small amount of liquid.

Side effects:

When using therapeutic doses, side effects are usually not expressed and are transient. Typically, these side effects disappear with a longer use of the drug Curantil® 25.

Side effects are listed below in descending frequency: often (> 1% - <10 % patients), infrequently (> 0.1 % - <1 % patients), rarely (> 0.01% - <0.1 % patients), very rarely (<0.01 % patients), including individual reports.

From the cardiovascular system:

infrequently: palpitations, tachycardia, bradycardia, blood flushes to the face, coronary steal syndrome (with doses more than 225 mg / day), lowering blood pressure;

From the digestive system:

infrequently: nausea, vomiting, diarrhea, epigastric pain;

From the side of blood and the system of homeostasis:

infrequently: thrombocytopenia, changes in the functional properties of platelets;

rarely: bleeding;

rarely: increased bleeding.

Other:

rarely: weakness, dizziness, ear congestion, noise in the head, headache, facial flushing, arthritis, myalgia, rhinitis, allergic reactions.

Overdose:

Symptoms: general vasodilation accompanied by hypotension; angina pectoris, tachycardia, weakness, dizziness, redness of the face.

Treatment: symptomatic therapy.

In case of an overdose, it is necessary to induce vomiting and to wash the stomach. The dilating effect of Curantil® 25 can be quenched by slow intravenous injection of aminophylline (50-100 mg for 60 seconds). If after this the symptoms of angina persist, then you can apply nitroglycerine under the tongue.

Interaction:

Xanthine derivatives (caffeine preparations, coffee, tea) can weaken the vasodilating effect of the drug Curantil® 25. The use of Curantil® 25 simultaneously with anticoagulants (heparin) or acetylsalicylic acid increases the risk of hemorrhagic complications, which must be taken into account when combined.

Curantil® 25 can enhance the effect of antihypertensive drugs.

Curantil® 25 can reduce the effect of cholinesterase inhibitors. The antiaggregant effect of the drug Curantil® 25 is enhanced by simultaneous administration with antibiotics of the penicillin, cephalosporin series, tetracycline and chloramphenicol.

Antacids reduce the maximum concentration of the drug Curantil® 25 due to reduced absorption.

Effect on the ability to drive transp. cf. and fur:

In connection with the possible dizziness, weakness and low blood pressure during the period of taking the drug Curantil® 25, the ability to concentrate and speed of psychomotor reactions in patients may be reduced. Therefore, during the period of treatment with the drug Curantil® 25, care should be taken when driving vehicles and engaging in potentially dangerous activities requiring increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Tablets coated with a coating, 25 mg.

Packaging:

For 100 tablets, coated with a shell, into a bottle of colorless glass with a plastic stopper.

1 bottle per cardboard pack together with instructions for use.

Storage conditions:

Store in a dark place at a temperature of no higher than 25 ° C.

Keep the medicine out of the reach of children!

Shelf life:

5 years.

Do not use after the expiration date stated on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N016001 / 01

Date of registration:13.10.2009 / 26.09.2014

Expiration Date:Unlimited

The owner of the registration certificate:BERLIN-PHARMA, CJSC BERLIN-PHARMA, CJSC Russia

Manufacturer: & nbsp

BERLIN-CHEMIE, AG Germany

Representation: & nbspBERLIN-PHARMA, CJSCBERLIN-PHARMA, CJSC

Information update date: & nbsp07.02.2018

Illustrated instructions

Instructions

Curantil® 25 (Curantyl® 25)